OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kamdar on the Benefit of Liso-Cel Therapy Across Lymphoma Subgroups

August 28th 2024

Manali Kamdar, MD, discusses which populations of lymphoma subtypes, such as MCL, may derive the most benefit from liso-cel treatment.

Dr Cigliola on Potential Implications of the SURE-01 and SURE-02 Trials in MIBC

August 27th 2024

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

Dr Forsyth on the Potential Utility of Intrathecal cDC1s in Leptomeningeal Disease

August 27th 2024

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

Dr Daver on the Potential Role of MRD Assessment in AML Treatment

August 27th 2024

Naval G. Daver, MD, discusses the potential role of minimal residual disease assessments in acute myeloid leukemia.

Dr El-Khoueiry on Immune Suppression in Advanced HCC After Checkpoint Inhibitors

August 27th 2024

Anthony B. El-Khoueiry, MD, discusses immune suppression in advanced hepatocellular carcinoma post-checkpoint inhibitor therapy.

Dr Sonneveld on the Background of the D-VRd Regimen in Newly Diagnosed Myeloma

August 27th 2024

Pieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.

Dr Townsend on the Future Analysis of Prostate Cancer Driver Mutations Using Neoplasm Tissue Samples

August 27th 2024

Jeffrey P. Townsend, PhD, discusses analysis of prostate cancer driver mutations using early neoplasm tissue samples.

Dr Yekedüz on the Importance of the KEYNOTE-564 Trial in Adjuvant ccRCC

August 27th 2024

Emre Yekedüz, MD, discusses a case study on a patient with clear cell renal cell carcinoma, highlighting adjuvant treatment options for this individual.

Dr Haffty on Radiation in Node-Positive Breast Cancer That Converts to Node Negative

August 26th 2024

Bruce G. Haffty, MD, MS, FACR, FASTRO, discusses the use of radiation in node-positive breast cancer patients who convert to node-negative status after neoadjuvant chemotherapy.

Dr Mehta on the Sequencing of CAR T-Cell Therapy and Bispecific Antibodies in Lymphoma

August 26th 2024

Amitkumar Mehta, MD, discusses complexities and considerations around sequencing CAR T-cell therapies and bispecific antibodies in lymphoma.

Dr El-Jawahri on the Effects of Sexual Health Interventions in HSCT Recipients

August 26th 2024

Areej El-Jawahri, MD, discusses a trial investigating a multimodal intervention to enhance sexual function in patients who have previously received HSCT.

Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRC

August 26th 2024

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Dr Saad on the Potential Predictive Value of IL7 SNPs in RCC

August 26th 2024

Eddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.

Dr Devoe on Next Steps for Evaluating ELI-002 7P in MRD+ KRAS-Mutant PDAC and CRC

August 26th 2024

Craig E. Devoe, MD, MS, discusses next steps for assessing the ELI-002 7P vaccine in patients with MRD–positive, KRAS-mutant PDAC and CRC.

Dr Kelly on Ongoing Trials in Patients With GIST

August 26th 2024

Ciara Kelly, MBBCh, BAO, discusses ongoing trials to further enhance the treatment of patients with gastrointestinal stromal tumor.

Dr Singhi on Areas of Interest in Metastatic Lung Cancer Research

August 26th 2024

Eric Kumar Singhi, MD, discusses potential areas of research interest in the treatment of patients with metastatic lung cancer.

Dr Yekedüz on the Benefits of Biomarker-Driven Treatment in Kidney Cancer

August 26th 2024

Emre Yekedüz, MD, discusses key takeaways from IMmotion010, highlighting the importance of biomarker-driven treatment in patients with kidney cancer.

Dr Koff on BTK Inhibitors vs Venetoclax-Based Regimens in First-Line CLL

August 23rd 2024

Jean L. Koff, MD, MS, discusses considerations around using BTK inhibitors vs venetoclax-based regimens in first-line chronic lymphocytic leukemia.

Dr Chambers on the Role of Genetic Testing and PARP Inhibitors in Ovarian Cancer

August 23rd 2024

Laura J. Chambers, DO, discusses the role of genetic testing and PARP inhibitor maintenance therapy for patients with ovarian cancer.

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

August 23rd 2024

Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.